Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of lapatinib + capecitabine in elderly HER2-positive metastatic breast cancer
2009-015981-73Phase 2Active
- Sponsor
- Unicancer
- Start
- Oct 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib and capecitabine in breast cancer, sponsored by Unicancer. Primary endpoints: Composite clinical benefit and tolerance at 4 months, Duration of clinical benefit and 2 more. Started Oct 2009; status: active.
02
Drugs
lapatinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-015981-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015981-73.